FindTrial
Sign In

MULTICENTRIC, PERSPECTIVE, RANDOMIZED TRIAL TO ASSESS THE INTRAOPERATIVE USE OF HYPERTHERMIC CHEMOTHERAPY IN LOCALLY ADVANCED NON SMALL CELL LUNG CANCER. COMPARISON BETWEEN LOCO-REGIONAL + SYSTEMIC CHEMOTHERAPY VS CONVENTIONAL TREATMENT - HTIPC

MULTICENTRIC, PERSPECTIVE, RANDOMIZED TRIAL TO ASSESS THE INTRAOPERATIVE USE OF HYPERTHERMIC CHEMOTHERAPY IN LOCALLY ADVANCED NON SMALL CELL LUNG CANCER. COMPARISON BETWEEN LOCO-REGIONAL + SYSTEMIC CHEMOTHERAPY VS CONVENTIONAL TREATMENT - HTIPC

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005980-83-IT
Enrollment
Unknown
Registered
2008-08-04
Start date
2008-01-27
Completion date
Unknown
Last updated
2014-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

NON SMALL CELL LUNG CANCER PATIENTS MedDRA version: 9.1 Level: HLT Classification code 10024973 Term: Lower respiratory tract neoplasms

Interventions

Trade Name: CISPLATINO EBEWE Pharmaceutical Form: Irrigation solution INN or Proposed INN: Cisplatin Concentration unit: mg/m2 milligram(s)/square meter Concentration type: equal Concentration number:

Sponsors

CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - T2, T3, T4 N0 N1 M0 NON SMALL CELL LUNG CANCER Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: - M1, T1 - OTHER NEOPLASTIC DISEASES - RENAL, HEPATIC, BONE MARROW FAILURE

Design outcomes

Primary

MeasureTime frame
Main Objective: GLOBAL SURVIVAL EVALUATION;Secondary Objective: - DISEASE FREE SURVIVAL - MORTALITY AND MORBIDITY - RISK FACTORS - TOXICITY - POSITIVE PREDICTIVE FACTORS TO LOCO-REGIONAL TREATMENT;Primary end point(s): GLOBAL SURVIVAL EVALUATION—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026